All In Biotech

Drug Trial Radar · NCT01755676

Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults

A Prospective Study, Parallel, Double-blind, Multicenter for Evaluation of Efficacy of Orlistat 60 mg as Adjuvant Treatment of Obesity in Adults

Last checked: Nov 20, 2026Latest source record: Apr 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 638 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

638

Actual

Start

Sep 2016

Primary completion

Dec 2017

Study completion Dec 21, 2017

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Dec 24, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate efficacy of orlistat 60 mg as adjuvant treatment of Obesity in adults.

Conditions

  • Obesity

Interventions

  • Orlistat 60 mgDrug

    1 tablet 3 times a day

  • PlaceboOther

    1 tablet 3 times a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of Orlistat 60 mg associated with diet and exercise in relation to placebo associated with diet and exercise in obesity treatment based on weight loss.Time frame: 112 days

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Centro de Medicina Reprodutiva Dr Carlos Isaia Filho

    Porto Alegre, Rio Grande do Sul, Brazil

  • Loema

    Campinas, São Paulo, Brazil

  • Allergisa

    Campinas, São Paulo, Brazil

  • CIPMED

    Jaú, São Paulo, Brazil

  • Marcio Antonio Pereira Clinica de Endocrinologia

    São José dos Campos, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.